Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

Rhea-AI Summary

Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced it will release its full-year 2024 financial results on Friday, February 28, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day to discuss results and provide a business update. An archived replay will be available on the company's website following the conference.

News Market Reaction

-4.88%

1 alert

-4.88% News Effect

On the day this news was published, LGVN declined 4.88%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

MIAMI, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.

Conference Call and Webcast Details:

Conference Call Number:	1.877.407.0789
Conference ID:	13751432
Call meTM Feature:	Click Here
Webcast:	Click Here

An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B^TM development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

FAQ

When will Longeveron (LGVN) release its full-year 2024 financial results?

Longeveron will release its full-year 2024 financial results on Friday, February 28, 2025, after U.S. market close.

What time is Longeveron's (LGVN) earnings call for full-year 2024 results?

Longeveron's earnings call and webcast is scheduled for February 28, 2025, at 4:30 p.m. ET.

Where can I access the replay of Longeveron's (LGVN) 2024 earnings call?

An archived replay of the webcast will be available in the 'Events & Presentations' section of Longeveron's company website.

What will be discussed in Longeveron's (LGVN) February 28, 2025 conference call?

The conference call will cover Longeveron's full-year 2024 financial results and provide a business update.